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ABSTRACT 
 
Objectives: Zinc is an important trace element in human nutrition and its deficiency is a worldwide 
problem. Zinc deficiency incidence is predominantly high in many diseases such as ESRD (End 
Stage Renal Disease) patients undertaking hemodialysis (HD). Beside, hypertension and cardiac 
output, is a predictor of cardiovascular mortality in HD patients. This study investigated the effects 
of zinc supplementation on blood pressure (BP) and complete blood count (CBC) in HD patients. 
Materials and Methods: In a randomized, double-blind, and placebo-controlled trial, Sixty-five HD 
patients were randomly divided into two groups. Patients in group I and group II received placebo 
and Zn supplementation (100 mg/day) respectively for two months. After withdrawing for the 
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duration of the next two months, the study was continued as a crossover design for another two 
months (group I and II received zinc supplementation and placebo, respectively). Systolic and 
diastolic BP, cardiac ejection fraction (EF), and CBC were measured at the 0
th
, 60
th
, 120
th
, and 
180th days. Statistical analyses were performed using SPSS software. 
Results: Zinc supplementation resulted in a significant increase in the mean red blood cell (RBC), 
Hematocrit (Hct), whereas a significant decrease was seen in systolic and diastolic BP. Changes 
observed in the placebo group were not significant.  
Conclusion: Zinc supplementation for two months improved the systolic and diastolic BP, RBC, 
and Hct in HD patients. 
 
 
Keywords: Zinc supplementation; hemodialysis; blood pressure; complete blood count. 
 
1. INTRODUCTION  
 
End Stage Renal Disease (ESRD), a complete 
and irreversible kidney failure, is the advanced 
form of chronic kidney disease (CKD). There are 
more than one million ESRD sufferers worldwide 
and many of them die from causes related to 
kidney failure each year. Hypertension is the 
second leading cause of chronic kidney disease 
(CKD) after diabetes. Furthermore, renal failure 
is the most common form of secondary 
hypertension and available evidence proposes 
that, it is an important risk factor for 
cardiovascular mortality and morbidity [1,2]. 
Therefore, hypertension is both a cause and 
result of kidney disease. Hypertension can be a 
risk factor for CKD in two general ways. In the 
first pathway, chronic hypertension causes 
glomerular ischemia and arterial injury and 
glomerulopathy. As a result, it reduces 
glomerular blood flow and causes nephropathy. 
In the second pathway, chronic hypertension 
causes the loss of auto-regulation of afferent 
arterioles and glomerular systemic hypertension. 
Therefore, this process leads to 
glomerulosclerosis and renal failure [3]. In 
patients with CKD, sodium misbalance leads to 
an increase in blood pressure. Initially, the 
extracellular fluid and peripheral resistance are 
increased, which these cause an increase in 
blood pressure. In addition, the activation of the 
renin-angiotensin system may stimulate the 
sympathetic nervous system and cause 
hypertension [2]. 
 
The prevalence of hypertension in patients on 
hemodialysis is as high as 90%. Controls of 
hypertension in the ESRD patients are 
recommended [3]. Therefore, the necessity to 
search for appropriate preventive and 
management strategies should be the concern of 
health care providers. Pathogenesis of 
hypertension is wide-spread, for this reason, 
many strategies such as, decreased oxidative 
stress, and increased antioxidant activities 
proposed for management of this abnormality in 
ESRD patients [4,5].  
 
Several studies have demonstrated that essential 
trace elements play important roles in states of 
cardiovascular diseases such as hypertension 
[6]. Zinc, one of the essential trace element and 
intracellular ion and the second most abundant 
transition metal in organisms after iron, is the 
only metal which appears in all enzymes [7]. Zinc 
is complicated in numerous biochemical 
functions. More than 300 enzymes to function 
and approximately 2000 transcription factors for 
gene expression require this element [8]. 
 
Although essentiality of zinc for humans and its 
deficiency was identified during the past 50 
years, it has become seeming that insufficiency 
of zinc in humans is a prevalent nutritional 
deficiency of zinc may affect approximately 2 
billion of global population [9,8]. The current work 
was designed with the aim of investigating the 
potentials of zinc supplementation in the 
ameliorating of hypertension and CBC indices in 
HD patients. 
 
2. METHODS AND MATERIALS 
 
In this study 78 chronic hemodialysis patients 
were selected to double-blind randomized 
controlled trial (RCT) at Tabriz Imam Khomeini 
Hospital. This experiment was performed 
according to the Declaration of Helsinki as well 
as the International Medical Research and was 
approved by the ethics committee of Tabriz 
University of Medical Sciences. An informed 
agreement was obtained from each volunteer. 
Inclusion and exclusion criteria for participation in 
the study was shown in the Table 1. Five patients 
were excluded from the study, 3 died because of 
cardiac arrest, 2 were receiving antibiotics, and 3 
were excluded because of zinc intolerance 
(nausea).
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Table 1. Inclusion and exclusion criteria for participation in the study 
 
Inclusion Chronic hemodialysis patients 
Exclusion Hemodialysis for less than 6 months;  
Hospitalization apart from chronic renal failure; 
Any sign of gastrointestinal disorders; 
Smoking; 
Being a candidate for kidney transplantation; Pregnancy or lactation; 
Consumption of glucocorticoids, antibiotics, estrogens, and contraceptives (in females). 
 
Sixty-five patients [41 males (63.1%) and 24 
females (36.9%)] with a mean age of 52.77 ± 
12.68 years (26-80 ages) completed the study. 
The etiology of ESRD was chronic 
glomerulonephritis (n=16), diabetic nephropathy 
(n=9), polycystic kidney disease (n =5), chronic 
interstitial nephropathy (n=5), urological 
problems (n=4), Hypertension (n=7), vascular 
disease (n=6), Urinary tract obstruction or 
dysfunction (n=2), Hereditary nephropathy (n=5), 
and unconfirmed etiology of HD (n=6). All of the 
patients were on HD 3 times per week (each time 
for 4 hours) by using a cellulosic membrane to 
maintain a minimum Kt/V urea index of 1.2 per 
session.  
 
Patients were randomly divided into two groups: 
Group I included 35 patients (22 males and 13 
females) with a mean age of 50.97 ± 11.50 
years. The duration of dialysis was 42.03 ± 27.75 
months. This group received 100 mg cornstarch 
capsules (two-per-day) as placebo for 2 months. 
Group II included 30 patients (19 males and 11 
females) with a mean age of 54.87 ± 13.74 
years. The duration of dialysis was 47.31 ± 22.78 
months. This group received 100 mg/day of 
elemental zinc sulfate (as two 220 mg zinc 
heptahydrate, ALHAVI Co., Tehran, Iran) for 2 
month at the same time with group I. 
 
The placebo and zinc were withdrawn for the 
duration of the next 2 months, and then the study 
was continued as a crossover design for another 
2 months (group I and II received zinc and 
placebo, respectively). In this study, none of the 
groups were aware of being in the 
supplementation or placebo group. Also, the 
experimenter was not aware of the samples. For 
the placebo group, capsules similar to zinc 
supplementation were used, but the capsules 
were filled with corn starch. Our study, with little 
difference, is similar to Finckh et al. In this study, 
a double-blind and crossover study, randomly, 
there were two groups that administered the 
methotrexate and placebo for three months. 
Then, they washed out for two months, and 
again for three months, the study was as 
Crossover. As, before the wash out, the group 
receiving methotrexate administered the placebo 
in the second trimester and the group receiving 
placebo administered methotrexate in the second 
trimester [10]. 
 
Overnight fast (12-h) blood samples were 
obtained before the start of zinc and placebo, at 
the 0
th
, 60
th
, 120
th
, and 180
th
 days in fasting. 
These Pre-dialysis blood samples were divided 
into a heparinized tube and a microtube 
containing EDTA (1.5 mg/mL) and then used for 
complete blood count (CBC) or centrifuged and 
stored at −18°C until other analyzed. 
 
Serum zinc level was determined by an atomic 
absorption spectrophotometry after a 1:5 dilution 
in double deionized water at 213.9 nm 
(ChemTech Analytical Co., Bedford, UK) using 
external standard calibration curve.  
 
Measurement of hemoglobin, hematocrit, white 
blood cells (WBC), and red blood cells (RBC) 
was performed with Sysmex KX-21N Automated 
Hematology Analyzer. Systolic and diastolic 
blood pressure was measured by cardiologists 
using a mercury sphygmomanometer with 
subjects in a supine position after five minutes of 
relaxing. 
 
All statistical analyses were performed using IBM 
SPSS statistics software (version 20; SPSS). 
Results are presented as mean ± SD. Between-
group comparisons were made using 
independent t-test. The differences between 
variables before and after intervention were 
compared using paired t-test. P-value <0.05 was 
considered statistically significant. 
 
3. RESULTS 
 
Table 2 represents the mean values of systolic 
and diastolic BP, EF, and CBC with differential 
levels in group I during the placebo (from day 0 
to day +60) and zinc supplementation (from day 
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+120 to day +180) periods. As shown in this 
table, there was a significant decrease in EF 
level after 60 days in the placebo group (P<0.05) 
whereas the other factors were not significantly 
changed. After the zinc supplementation period 
(from days +120 to +180), an increase was seen 
in EF (P<0.05). Blood pressure indicators 
including systolic and diastolic BP were 
decreased significantly (P<0.05). Hb 
(hemoglobin), Hct levels as well as erythrocyte 
count improved significantly (P=0.011, P=0.043, 
and P<0.05 respectively). White blood cell count 
(WBC) differential such as neutrophils, and 
lymphocytes were not changed considerably. 
 
Table 3 shows the mean values of systolic and 
diastolic BP, EF, and CBC with differential levels 
in group II during the zinc supplementation (from 
day 0 to day +60) and placebo (from day +120 to 
day +180) periods. There were increases in EF, 
Hct, and RBC levels (P<0.05, P=0.016, and 
P<0.05 respectively) and significant decrease in 
systolic BP (P<0.05) and diastolic BP (P<0.05) 
after 60 days in zinc supplementation period. 
Whereas, there were no statistically or clinically 
significant change in mean hemoglobin levels in 
this period. After the placebo period (from days 
+120 to +180), a reduction was found in the 
mean EF. Significant changes were not shown in 
other factors. Comparison of significance level of 
study groups at different time intervals was 
showed in the Table 4. 
 
4. DISCUSSION 
 
According to the results of our study, in both 
group I and group II, the amount of Hb and Hct 
as well as erythrocyte count, indicating anemia in 
HD patients, was lower than normal. 
Administration of Zn supplements improved 
these factors significantly. Increasing of Hb in 
group II didn't signify. Erythrocytes due to 
intracellular enzymes such as SOD, catalase, 
and glutathione are important components of 
blood antioxidants [11]. One of the possible 
causes of renal anemia and reduce the life of 
RBCs is due to oxygen free radical attack 
(because of increased oxidative stress in 
patients) in their membranes. This effect, 
reduces intravascular hemolysis and RBCs half-
life [12-14]. Effect of Zn in improving anemia, 
appear to be at least partially due to the 
improvement of antioxidant status and oxidative 
stress reduction. Improving oxidative stress and 
anemia can have a synergistic effect on each 
other [15]. Therefore, correction of renal anemia 
may be effective in strengthening the capacity of 
the antioxidant in the body. Siems et al. reported 
that lipid peroxidation in patients with Hb<10 g/dl 
is more than that in patients with Hb>10 g/dl [14]. 
Other study, reported that the decrease of Hb 
and RBCs in rats is correlated with deficiency of 
Zn level [16]. 
 
The systolic/diastolic blood pressure was 146/81 
mmHg in our study. Blood pressure did not 
change significantly in the placebo period, but Zn 
supplementation resulted in a significant 
reduction in systolic and diastolic blood pressure. 
Hypertension is a common phenomenon in HD 
patients [17-19]. High blood pressure can be a 
cause or consequence of chronic kidney disease 
[20]. Mechanisms of hypertension in renal failure 
are complex and include neural and hormonal 
effects [21,22]. Galley et al. reported that the 
administration of Zn, vitamins C and E for eight 
weeks reduced systolic blood pressure [13]. 
Importance of peroxidation and oxidative stress 
on the pathogenesis of hypertension was 
reported by Russo et al. [23]. 
 
The EF baseline, in the range of 52% -55% of 
patients who are prescribed in the absence of Zn 
(placebo period) has decreased after 60 days, 
indicating the rapid effects of acute uremia 
conditions in the performance of the heart. 
Decreasing in this performance probably by 
reducing trace elements such as Zn, as one of 
the factors to be considered. Decreasing average 
systolic function and EF level in about 20% of HD 
patients was reported by Virga et al. [24]. In our 
study, administration of Zn not only prevents the 
reducing of EF in patients, but also it has been 
effective in improving EF, is an indication of the 
beneficial effects of Zn complementation. It is 
possible that at least the part of this effect is 
because of improving anemia as well as 
decreasing blood pressure in these patients. In 
the previous study, it was shown that there is a 
direct relationship between the level of Zn and 
antioxidant status in the hemodialysis patients 
[25]. There is growing evidence that oxidative 
damages and many of the complications in HD 
patients are related to accelerated 
atherosclerosis. Thus, Zinc deficiency and, 
consequently, oxidative stress can exacerbate 
atherosclerosis as a heart disease is involved in 
long-term HD patients [13,26,14,27]. In addition, 
the harmful consequence of high blood pressure 
in chronic kidney disease is the rapid decline in 
renal and heart function [20]. This suggests the 
relationship between blood pressure and 
cardiovascular disease. 
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 Table 2. Systolic and diastolic body pressure (BP), cardiac ejection fraction (EF), and complete blood count (CBC) indices in group I during the 
placebo period (at Days 0 and +60) and the supplementation period (at Days +120 and +180), Males (n=22), females (n=13) 
 
Variables Placebo period Supplementation period 
Day 0        
(mean+SD) 
Day +60   
(mean+SD) 
P-value Day +120 
(mean+SD) 
Day +180 
(mean+SD) 
P-value 
BMI 
Male 
Female 
23.83±3.68 
23.68 
24.08 
24.10±4.01 
23.86 
24.50 
NS 23.44±3.30 
23.49 
23.35 
23.99±3.37 
23.90 
24.13 
NS 
Dietary zinc (mg/day) 
Male 
Female 
3.76±1.97 
4.17 
3.07 
3.62±1.56 
3.89 
3.27 
NS 
 
3.70±1.53 
3.97 
3.24 
3.84±1.59 
4.07 
3.44 
NS 
 
 
Serum zinc (g/dl) 
Male 
Female 
79.49±13.12 
80.41 
77.92 
79.17±11.34 
79.36 
78.84 
NS 80.37±10.69 
82.36 
77.0 
111.37±20.43 
112.63 
109.23 
<0.001* 
 
Systolic BP (mmHg) 
Male 
female 
146.00±19.99 
146.14 
145.77 
144.29±22.63 
145.45 
142.31 
NS 145.71±21.04 
146.36 
144.61 
139.86±21.37 
139.10 
141.15 
<0.05* 
Diastolic BP (mmHg) 
Male 
Female 
81.23±7.96 
82.04 
79.85 
81.14±9.93 
82.04 
79.61 
NS 82.71±8.52 
84.54 
79.61 
80.29±8.99 
82.27 
76.92 
<0.05* 
% EF 
Male 
Female 
55.37±8.72 
55.14 
55.77 
54.14±8.44 
53.77 
54.77 
NS 53.11±8.36 
52.77 
53.69 
54.40±8.15 
53.68 
55.61 
NS 
Hb (g/dl) 
Male 
Female 
9.57±1.95 
10.31 
8.31 
9.59±1.74 
9.31 
9.04 
NS 9.31±1.73 
9.61 
8.81 
9.92±1.94 
10.4 
9.1 
0.011* 
Hct (%) 
Male 
Female 
29.49±5.79 
31.62 
25.89 
29.59±5.11 
30.57 
27.92 
NS 29.37±5.11 
30.50 
27.46 
30.88±5.67 
32.26 
28.54 
0.043* 
RBC (×106/l) 
Male 
Female 
3.39±0.71 
3.54 
3.14 
3.40±0.68 
3.39 
3.44 
NS 3.27±0.69 
3.23 
3.33 
3.50±0.81 
3.58 
3.35 
<0.05* 
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Variables Placebo period Supplementation period 
Day 0        
(mean+SD) 
Day +60   
(mean+SD) 
P-value Day +120 
(mean+SD) 
Day +180 
(mean+SD) 
P-value 
WBC (/l) 
Male 
Female 
6062.86±1743.24 
6063.64 
6061.54 
5722.86±1574.63 
5900 
5423.08 
NS 5440.00±1627.38 
5531.82 
5264.81 
5625.71±1803.65 
5586.36 
5692.31 
NS 
Neutrophil (%) 
Male 
Female 
60.40±6.38 
61.73 
58.15 
59.54±7.20 
60.5 
57.92 
NS 59.46±7.75 
60.64 
57.46 
59.91±6.61 
60.14 
59.54 
NS 
Lymphocyte (%) 
Male 
Female 
35.03±6.15 
34.27 
36.31 
35.51±6.30 
35.04 
36.31 
NS 35.63±7.06 
34.91 
36.85 
34.46±6.80 
34.73 
34.00 
NS 
*Statistically Significant. NS: Non-Significant. SD: Standard Deviation 
 
Table 3. Systolic and diastolic body pressure (BP), cardiac ejection fraction (EF), and complete blood count (CBC) indices in group II during the 
supplementation period (at days 0 and +60) and the placebo period (at days +120 and +180), Males (n=19), females (n=11) 
 
Variables Supplementation period Placebo period 
Day 0       
(mean+SD) 
Day +60   
(mean+SD) 
P-value Day +120 
(mean+SD) 
Day +180 (mean+SD) P-value 
BMI 
Male 
Female 
24.24+7.86 
24.96 
23.02 
23.37+4.39 
23.41 
23.30 
NS 23.33+4.36 
23.34 
23.30 
23.40+4.31 
23.42 
23.38 
NS 
Dietary zinc (mg/day) 
Male 
Female 
2.94+1.66 
3.26 
2.38 
2.71+1.33 
2.87 
2.43 
NS 2.86+1.07 
3.11 
2.42 
2.77+1.24 
3.05 
2.28 
NS 
Serum zinc (g/dl) 
Male 
Female 
77.40+14.51 
81.63 
70.09 
103.93+14.47 
106.32 
99.82 
<0.001* 94.73+15.61 
97.16 
90.54 
88.07+12.40 
91.89 
81.45 
0.003* 
Systolic BP (mmHg) 
Male 
Female 
150.17+23.29 
151.05 
148.64 
146.17+20.79 
146.05 
146.36 
<0.05* 146.67+23.32 
146.05 
147.73 
146.67+22.45 
145.79 
148.18 
NS 
Diastolic BP(mmHg) 
Male 
Female 
82.33+8.88 
83.16 
80.91 
79.67+7.87 
81.32 
76.82 
<0.05* 81.07+8.51 
81.58 
80.18 
80.83+8.31 
81.56 
79.54 
NS 
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Variables Supplementation period Placebo period 
Day 0       
(mean+SD) 
Day +60   
(mean+SD) 
P-value Day +120 
(mean+SD) 
Day +180 (mean+SD) P-value 
% EF 
Male 
Female 
52.20+11.00 
49.58 
56.73 
54.33+9.43 
52.74 
57.09 
NS 53.73+10.39 
51.53 
57.54 
52.67+10.50 
50.26 
56.82 
NS 
Hb (g/dl) 
Male 
Female 
9.59+1.80 
9.97 
8.94 
9.96+1.78 
10.34 
9.3 
NS 9.62+1.89 
10.10 
8.87 
9.20+1.71 
9.66 
8.4 
NS 
Hct (%) 
Male 
Female 
29.78+5.33 
30.34 
27.95 
31.28+4.92 
32.37 
29.41 
0.016* 30.13+5.64 
31.68 
27.45 
28.98+5.10 
29.97 
27.27 
NS 
RBC (×106/l) 
Male 
Female 
3.33+0.73 
3.35 
3.29 
3.51+0.76 
3.56 
3.44 
<0.05* 3.27+0.79 
3.35 
3.12 
3.14+0.69 
3.17 
3.09 
NS 
WBC (/l) 
Male 
Female 
5610.00+1262.82 
5636.84 
5563.64 
5470.00+1393.37 
5326.32 
5718.18 
NS 5550.00+2077.26 
5715.79 
5263.64 
5576.67+2048.33 
5694.74 
5372.73 
NS 
Neutrophil (%) 
Male 
Female 
60.90+6.67 
60.37 
61.82 
61.77+6.39 
61.26 
62.64 
NS 62.07+8.53 
61.95 
62.27 
62.33+8.69 
62.42 
62.18 
NS 
Lymphocyte (%) 
Male 
Female 
35.20+6.13 
36.42 
33.09 
33.27+7.07 
35.00 
30.27 
NS 32.90+7.08 
34.10 
30.82 
31.83+7.09 
32.00 
31.54 
NS 
*Statistically Significant. NS: Non-Significant. SD: Standard Deviation
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Table 4. Comparison of significance level of study groups at different time intervals 
 
Time Point Variables Group 1 Group 2 
 P-value P-value 
 
 
 
Day 0 – Day +60 
 
 
 
 
BMI NS NS 
Dietary zinc (mg/day) NS NS 
Serum zinc (g/dl) NS <0.001* 
Systolic BP (mmHg) NS <0.05* 
Diastolic BP (mmHg) NS <0.05* 
% EF NS NS 
Hb (g/dl) NS NS 
Hct (%) NS 0.016* 
RBC (×10
6
/l) NS <0.05* 
WBC (/l) NS NS 
Neutrophil (%) NS NS 
Lymphocyte (%) NS NS 
 
 
 
 
Day +120 - Day +180 
BMI NS NS 
Dietary zinc (mg/day) NS NS 
Serum zinc (g/dl) <0.001* 0.003* 
Systolic BP (mmHg) <0.05* NS 
Diastolic BP (mmHg) <0.05* NS 
% EF NS NS 
Hb (g/dl) 0.011* NS 
Hct (%) 0.043* NS 
RBC (×106/l) <0.05* NS 
WBC (/l) NS NS 
Neutrophil (%) NS NS 
Lymphocyte (%) NS NS 
*Statistically Significant. NS: Non-Significant 
 
5. CONCLUSION 
 
In conclusion, zinc supplementation improved 
blood pressure (BP), cardiac ejection fraction 
(EF), and erythrocyte count in HD patients. 
Increasing cardiac ejection fraction and the 
number of red blood cells as well as improving 
blood pressure can increase life expectancy in 
patients undergoing hemodialysis. One of the 
limitations of this study is the lack of 
measurement of albumin and some other ions, 
including cupper which were not measured due 
to insufficient serum.  Further Studies on the 
mechanisms by which heart and blood indices 
are influenced as a result of zinc 
supplementation in HD patients should be 
undertaken. 
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